Genetic screening of elite Indian athletes identified a 4.7% prevalence of the MYBPC3 d25bp heterozygous genotype, which was associated with mild concentric left ventricular hypertrophy.
Cross-Sectional (n=149)
A 4.7% prevalence of the MYBPC3 d25bp variant was found among elite Indian athletes, which was associated with mild concentric LVH, suggesting a potential role for genetic testing in preparticipation screening to mitigate sudden cardiac death risk.
Background: Hypertrophic cardiomyopathy (HCM) is one of the leading congenital causes of sudden cardiac death/sudden cardiac arrest (SCD/SCA) among young competitive athletes. HCM is genetically inherited in an autosomal dominant manner, and genetic mutations in any one of the 12 myocardial contractile filament protein-encoding genes may be attributed to this heterogeneous disorder. Aims and Objectives: Therefore, our objective was to investigate the prevalence of the MYBPC3 d25bp variant among the athletic population in India, and the presence of HCM-associated pathological left ventricular hypertrophy (LVH) among the MYBPC3 d25bp genotype carrier athletes. Materials and Methods: Oral mouthwash samples were collected from a total of 149 elite athletes (age range: 18–36 years) and screened for MYBPC3 d25bp genotype. We performed resting and cardiac stress 12-channel electrocardiography and echocardiography evaluation on heterozygous MYBPC3 d25bp carrier athletes for HCM phenotype diagnosis. Results: We found 4.7% (7/149; 4 male and 3 female) prevalence of deleterious MYBPC3 d25bp heterozygous genotype among our sample athletes. Based on left ventricular mass index (LVMI) and relative wall thickness (RWT), we observed a mild form of concentric LVH among male (LVMI: 127.2 g/m 2 ; RWT: 0.59) and female (LVMI: 98.1 g/m 2 ; RWT: 0.52) carrier athletes. Conclusion: Based on these results, we recommend long-term clinical follow-ups for athletes carrying MYBPC3 d25bp heterozygous genotype coupled with concentric LVH, during their training and competition to differentiate between physiological training-associated cardiac adaptations and pathological left ventricular parameters and mitigate the potential risk of SCD/SCA. Furthermore, preparticipation screening for HCM and other cardiac anomalies should include genetic testing as well.
Shukla et al. (Thu,) conducted a cross-sectional in Hypertrophic cardiomyopathy risk (n=149). Genetic screening for MYBPC3 d25bp variant was evaluated on Prevalence of MYBPC3 d25bp variant. Genetic screening of elite Indian athletes identified a 4.7% prevalence of the MYBPC3 d25bp heterozygous genotype, which was associated with mild concentric left ventricular hypertrophy.